Literature DB >> 18485985

Nephrogenic systemic fibrosis is associated with transforming growth factor beta and Smad without evidence of renin-angiotensin system involvement.

Brent Kelly1, Matthew Petitt, Ramon Sanchez.   

Abstract

BACKGROUND: The mechanisms of fibrosis associated with nephrogenic systemic fibrosis (NSF) are largely unknown. Transforming growth factor beta (TGF-beta), a known profibrotic cytokine, is theorized to play a central role. The renin-angiotensin system has been linked with both TGF-beta expression and fibrosis in other organ systems.
OBJECTIVE: We sought to investigate whether these mechanisms were involved with NSF.
METHOD: Eleven biopsy specimens from 8 patients with NSF were evaluated by immunohistochemistry for the expression of TGF-beta, Smad 2/3, angiotensin-converting enzyme (ACE), and angiotensin II receptor 1 (AT1).
RESULTS: TGF-beta was detected in 8 of 11 samples of NSF. Smad 2/3 nuclear staining was seen in 8 of 11 samples. Conversely, only faint staining for ACE was seen in 2 of the 11 specimens. No AT1 staining was seen. LIMITATIONS: We did not perform our studies on a cohort of comparable patients with renal dysfunction without NSF. Our technique may not have been sufficiently sensitive to detect renin-angiotensin system involvement.
CONCLUSIONS: TGF-beta, as well as its second messengers, Smad 2/3, appears to be associated with the fibrosis seen in NSF. No definitive evidence of renin-angiotensin system involvement could be determined.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18485985     DOI: 10.1016/j.jaad.2008.02.038

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  6 in total

Review 1.  [Nephrogenic systemic fibrosis].

Authors:  Stefan Becker; Oliver Witzke; Andreas Kribben
Journal:  Med Klin (Munich)       Date:  2009-04-01

2.  Hyperphosphataemia sensitizes renally impaired rats to the profibrotic effects of gadodiamide.

Authors:  N Fretellier; Jm Idée; P Bruneval; S Guerret; F Daubiné; G Jestin; C Factor; N Poveda; A Dencausse; F Massicot; O Laprévote; C Mandet; N Bouzian; M Port; C Corot
Journal:  Br J Pharmacol       Date:  2012-02       Impact factor: 8.739

3.  Involvement of the renin-angiotensin system in the development of nephrogenic systemic fibrosis-like lesions in the RenTag mouse model.

Authors:  Sandra Sexton; Ryan Tulowitzki; Craig A Jones; Silvi Shah; George Hajduczok; Kenneth W Gross; Mandip Panesar
Journal:  Clin Exp Nephrol       Date:  2015-07-03       Impact factor: 2.801

Review 4.  Skin problems in chronic kidney disease.

Authors:  Dirk R J Kuypers
Journal:  Nat Clin Pract Nephrol       Date:  2009-02-03

5.  A moderate response to plasmapheresis in nephrogenic systemic fibrosis.

Authors:  Pelin Ustuner; Ozlem Karadag Kose; A Tulin Gulec; Ozlem Ozen
Journal:  Clin Pract       Date:  2011-11-29

6.  Understanding nephrogenic systemic fibrosis.

Authors:  Tushar Chopra; Kiran Kandukurti; Silvi Shah; Raheel Ahmed; Mandip Panesar
Journal:  Int J Nephrol       Date:  2012-11-04
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.